Skip to main content

Table 2 Gadolinium content in the blood, liver, femur, kidneys, and skin

From: Gadolinium retention in a rat model of subtotal renal failure: are there differences among macrocyclic GBCAs?

 

28 days post-treatment

56 days post-treatment

 

Group

GBCA

  

Blood (nmol Gd/mL)

 SN rats

1

Gadoteridol

0.101 ± 0.53

0.0116 ± 0.0046a4

n

7

8

2

Gadobutrol

0.099 ± 0.017c4

0.0167 ± 0.0086b4

n

8

7

3

Gadoterate

0.094 ± 0.026b4

0.0152 ± 0.072a4

n

9

8

 Healthy rats

4

Gadoteridol

0.045 ± 0.014c2,b3

0.004 ± 0.001a1,b2,a3

n

5

4

Liver (nmol Gd/g)

 SN rats

1

Gadoteridol

2.2 ± 1.3a4

0.64 ± 0.28

n

8

8

2

Gadobutrol

4.2 ± 1.8b4

1.39 ± 0.81a4

n

8

7

3

Gadoterate

3.9 ± 2.1b4

2.0 ± 1.1a4

n

9

7

 Healthy rats

4

Gadoteridol

0.295 ± 0.087a1,b2,b3

0.132 ± 0.031a2,a3

n

5

5

Femur (nmol Gd/g)

 SN rats

1

Gadoteridol

17.1 ± 5.4b4

15.4 ± 3.7c4

n

8

8

2

Gadobutrol

25.3 ± 9.5b4

24.9 ± 9.3b4

n

8

7

3

Gadoterate

20 ± 12a4

16 ± 10

n

9

8

 Healthy rats

4

Gadoteridol

6.6 ± 1.6b1,b2,a3

5.24 ± 0.19b2,c1

n

5

5

Kidneys (nmol Gd/g)

 SN rats

1

Gadoteridol

206 ± 70c2,b3,c4

50 ± 36b2,a3,a4

n

8

8

2

Gadobutrol

991 ± 153c1,c4

265 ± 82b1,b4

n

7

6

3

Gadoterate

1286 ± 269b1,c4

283 ± 144a1,a4

n

9

7

 Healthy rats

4

Gadoteridol

9.0 ± 3.2c1,c2,c3

4.0 ± 1.7a1,b2,a3

n

4

5

Skin (nmol Gd/g)

 SN rats

1

Gadoteridol

1.32 ± 0.38c4

0.475 ± 0.092c4

n

8

7

2

Gadobutrol

2.6 ± 1.6b4

0.71 ± 0.23a4

n

8

6

3

Gadoterate

2.0 ± 1.0a4

0.68 ± 0.43a4

n

7

8

 Healthy rats

4

Gadoteridol

0.42 ± 0.15c1,b2.a3

0.188 ± 0.005c1, a2, a3

n

4

4

  1. Values presented as mean ± SD. ap < 0.05; bp < 0.01; cp < 0.001. The number after the letter of the significance level indicates the group versus which there is a difference. See main text for actual p values